Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of non-toxic deletion mutants of protective antigen from Bacillus anthracis.

FEMS immunology and medical microbiology - 1 Aug 2005

Rhie Gi-eun, Park Young-Mia, Han Ji-Sun, Yu Jae-Yon, Seong Won-Keun, Oh Hee-Bok

Abstract excerpt

Current human anthrax vaccines available in the United States and Europe consist of alum-precipitated supernatant material from cultures of a toxigenic, nonencapsulated strain of Bacillus anthracis. The major component of human anthrax vaccine that confers protection is protective antigen (PA). A second-generation human vaccine using the recombinant PA (rPA) is being developed. In this study, to prevent the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bacterial
Share to Bacillus
Share to Bacillus anthracis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bacterial Toxins

Share to Chymotrypsin

Share to Guinea Pigs

Share to Neutralization Tests

Share to Trypsin

Source

Identifiers

PMID: 16019195
DOI: 10.1016/j.femsim.2005.05.009

Genes

MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of non-toxic deletion mutants of protective antigen from Bacillus anthracis.PMID 16019195Read ↗

Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.Semantic proximity Read ↗

A dominant negative mutant of Bacillus anthracis protective antigen inhibits anthrax toxin action in vivo.Semantic proximity Read ↗

Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax.Semantic proximity Read ↗

Anthrax vaccines.Semantic proximity Read ↗

Identification of new dominant-negative mutants of anthrax protective antigen using directed evolution.Semantic proximity Read ↗

Gln277 and Phe554 residues are involved in thermal inactivation of protective antigen of Bacillus anthracis.Semantic proximity Read ↗

Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background.Semantic proximity Read ↗

Anthrax protective antigen cleavage and clearance from the blood of mice and rats.Semantic proximity Read ↗

Next-Generation Bacillus anthracis Live Attenuated Spore Vaccine Based on the htrA(-) (High Temperature Requirement A) Sterne Strain.Semantic proximity Read ↗

Characterization of the UK anthrax vaccine and human immunogenicitySemantic proximity Read ↗

Soluble expression and purification of the anthrax protective antigen in E. coli and identification of a novel dominant-negative mutant N435C.Semantic proximity Read ↗

Characterization of dominant-negative forms of anthrax protective antigen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.